Citations

Clear

16280 citation(s) found for "Yu, David".

Global TravEpiNet: A National Consortium of Clinics Providing Care to International Travelers—Analysis of Demographic Characteristics, Travel Destinations, and Pretravel Healthcare of High-Risk US International Travelers, 2009–2011
LaRocque, Regina C. , Rao, Sowmya R. , Ansdell, Vernon, Yates, Johnnie, Schwartz, Brian S. , Knouse, Mark, Cahill, John D. , Hagmann, Stefan , Vinetz, Joseph M. , Connor, Bradley A., Goad, Jeffery A. , Oladele, Alawode, Álvarez, Salvador, Stauffer, William M. , Walker, Patricia F., Kozarsky, Phyllis E., Franco‐Paredes, Carlos , Dismukes, Roberta, Rosen, Jessica , Hynes, Noreen A. , Jacquérioz, Frédérique , McLellan, Susan , Hale, DeVon C., Sofarelli, Theresa A., Schoenfeld, David , Marano, Nina , Brunette, Gary W., Jentes, Emily S. , Yanni, Emad , Sotir, Mark J., Ryan, Edward T. , Lee, Jennifer

Mayo Clinic

Clinical Infectious Diseases | December 6, 2011 | Volume: 54 | Issue: 4 | Pages: 455-462

10.1093/cid/cir839 | PMID 22144534 Get It

Estimating the proportion of intracranial aneurysms likely to be amenable to treatment with the pipeline embolization device
Brinjikji, Waleed , Cloft, Harry J. , Kallmes, David F. , Fiorella, David , Lanzino, Giuseppe

Mayo Clinic

Journal of NeuroInterventional Surgery | December 3, 2011 | Volume: 5 | Issue: 1 | Pages: 45-48

10.1136/neurintsurg-2011-010165 | PMID 22140137 Get It

Objective A study was undertaken to estimate the fraction of intracranial aneurysms that might be amenable to treatment with the pipeline embolization device (PED), a current flow diverter device, and to determine the types of aneurysms that are probably not amenable to treatment with this device. Methods A retrospective analysis of 200 consecutive intracranial aneurysms as seen on three-dimensional rotational angiography images was conducted. Based on aneurysm and parent artery morphology, four independent observers experienced in the use of the PED judged the likelihood that a given aneurysm could theoretically be treated with one or more PED using a 5-point scale: grades 1 and 2 indicated amenability to treatment with multiple devices; grade 3 indicated amenability to treatment with one device; and grades 4 and 5 indicated the aneurysm would not be amenable to treatment with the PED. Aneurysms were analyzed on the basis of anatomical factors only. Rupture status was not considered. Interobserver agreement was determined. Results 94 of 200 aneurysms (47%) were judged to be likely to be amenable to treatment with the PED; 50 cases (25%) were judged to be amenable to the use of multiple overlapping devices while, in 44 cases (22%), coverage with a single device was preferred. There was a significant relationship between the location of the aneurysm and the grade of the aneurysm (p<0.0001). Conclusion On the basis of anatomical configuration, nearly half of the aneurysms in this study were likely to be amenable to treatment with the PED.
Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading
Tedford, Ryan J. , Mathai, Stephen C. , Girgis, Reda E. , Thiemann, David R. , Cingolani, Oscar H. , Mudd, James O., Redfield, Margaret M. , Lederer, David J. , Hassoun, Paul M. , Russell, Stuart D. , Borlaug, Barry A. , Kass, David A. , Lederer, David J , Tedford, Ryan J , Mathai, Stephen C

Mayo Clinic

Circulation | December 2, 2011 | Volume: 125 | Issue: 2 | Pages: 289-297

10.1161/circulationaha.111.051540 | PMID 22131357 Get It

Background— Right ventricular failure from increased pulmonary vascular loading is a major cause of morbidity and mortality, yet its modulation by disease remains poorly understood. We tested the hypotheses that, unlike the systemic circulation, pulmonary vascular resistance (R PA ) and compliance (C PA ) are consistently and inversely related regardless of age, pulmonary hypertension, or interstitial fibrosis and that this relation may be changed by elevated pulmonary capillary wedge pressure, augmenting right ventricular pulsatile load. Methods and Results— Several large clinical databases with right heart/pulmonary catheterization data were analyzed to determine the R PA -C PA relationship with pulmonary hypertension, pulmonary fibrosis, patient age, and varying pulmonary capillary wedge pressure. Patients with suspected or documented pulmonary hypertension (n=1009) and normal pulmonary capillary wedge pressure displayed a consistent R PA -C PA hyperbolic (inverse) dependence, C PA =0.564/(0.047+R PA ), with a near-constant resistance-compliance product (0.48±0.17 seconds). In the same patients, the systemic resistance-compliance product was highly variable. Severe pulmonary fibrosis (n=89) did not change the R PA -C PA relation. Increasing patient age led to a very small but statistically significant change in the relation. However, elevation of the pulmonary capillary wedge pressure (n=8142) had a larger impact, significantly lowering C PA for any R PA and negatively correlating with the resistance-compliance product ( P <0.0001). Conclusions— Pulmonary hypertension and pulmonary fibrosis do not significantly change the hyperbolic dependence between R PA and C PA , and patient age has only minimal effects. This fixed relationship helps explain the difficulty of reducing total right ventricular afterload by therapies that have a modest impact on mean R PA . Higher pulmonary capillary wedge pressure appears to enhance net right ventricular afterload by elevating pulsatile, relative to resistive, load and may contribute to right ventricular dysfunction.
Small (< 10-mm) incidentally found intracranial aneurysms, Part 2: treatment recommendations, natural history, complications, and short-term outcome in 212 consecutive patients
Loumiotis, Ioannis , Brown, Robert D., Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Lanzino, Giuseppe

Mayo Clinic

Neurosurgical Focus | December 1, 2011 | Volume: 31 | Issue: 6 | Pages: E4

10.3171/2011.9.focus11237 | PMID 22133187 Get It

Object The management of incidental small unruptured intracranial aneurysms (UIAs) is controversial and many factors need to be considered in the decision-making process. The authors describe a large consecutive series of patients harboring small incidental intracranial aneurysms. Treatment strategy, natural history, complications, and short-term outcomes are presented. Methods Between January 2008 and May 2011, the authors prospectively evaluated 212 patients with 272 small (< 10-mm) incidental aneurysms. Treatment recommendations (observation, endovascular treatment, or surgery), complications of treatment, and short-term outcomes were assessed. Results Recommended treatment consisted of observation in 125 patients, endovascular embolization in 64, and surgery in 18. Six patients were excluded from further analysis because they underwent treatment elsewhere. In the observation group, at a mean follow-up of 16.7 months, only 1 patient was moved to the embolization group. Seven (6%) of the 125 patients in the observation group died of causes unrelated to aneurysm. Sixty-five patients underwent 69 embolization procedures. The periprocedural permanent morbidity and mortality rates in patients undergoing endovascular treatment were 1.5% and 1.5%, respectively (overall morbidity and mortality rate 3.0%). In the surgery group no periprocedural complications were observed, although 1 patient did not return to her previous occupation. No aneurysmal rupture was documented in any of the 3 treatment groups during the follow-up period. Conclusions A cautious and individualized approach to incidental UIAs is of utmost importance for formulation of a safe and effective treatment algorithm. Invasive treatment (either endovascular or surgery) can be considered in selected younger patients, certain “higher-risk” locations, expanding aneurysms, patients with a family history of aneurysmal hemorrhage, and in those who cannot live their lives knowing that they harbor the UIA. Although the complication rate of invasive treatment is very low, it is not negligible. The study confirms that small incidental UIAs deemed to be not in need of treatment have a very benign short-term natural history, which makes observation a reasonable approach in selected patients.
BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
Kim, Kevin B. , Sosman, Jeffrey A. , Fruehauf, John P. , Linette, Gerald P. , Nguyen, Hoa , Cheverton, Peter, Chen, Daniel S. , Peterson, Amy , Carson, William E. , Markovic, Svetomir N. , McDermott, David F. , Weber, Jeffrey S. , Peterson, Amy , O'Day, Steven J , Carson, William E

Mayo Clinic

Journal of Clinical Oncology | November 29, 2011 | Volume: 30 | Issue: 1 | Pages: 34-41

10.1200/jco.2011.34.6270 | PMID 22124101 Get It

Purpose Metastatic melanoma, a highly vascularized tumor with strong expression of vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with or without bevacizumab in patients with previously untreated metastatic melanoma. Patients and Methods Patients were randomly assigned in a two-to-one ratio to carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m 2 ) and bevacizumab (15 mg/kg; CPB) or placebo (CP) administered intravenously once every 3 weeks. Progression-free survival (PFS) was the primary end point. Secondary end points included overall survival (OS) and safety. Results Two hundred fourteen patients (73% with M1c disease) were randomly assigned. With a median follow-up of 13 months, median PFS was 4.2 months for the CP arm (n = 71) and 5.6 months for the CPB arm (n = 143; hazard ratio [HR], 0.78; P = .1414). Overall response rates were 16.4% and 25.5%, respectively (P = .1577). With 13-month follow-up, median OS was 8.6 months in the CP arm versus 12.3 months in the CPB arm (HR, 0.67; P = .0366), whereas in an evaluation 4 months later, it was 9.2 versus 12.3 months, respectively (HR, 0.79; P = .1916). In patients with elevated serum lactate dehydrogenase (n = 84), median PFS and OS were longer in the CPB arm (PFS: 4.4 v 2.7 months; HR, 0.62; OS: 8.5 v 7.5 months; HR, 0.52). No new safety signals were observed. Conclusion The study did not meet the primary objective of statistically significant improvement in PFS with the addition of bevacizumab to carboplatin plus paclitaxel. A larger phase III study will be necessary to determine whether there is benefit to the addition of bevacizumab to carboplatin plus paclitaxel in this disease setting.
A 71-Year-Old Woman with Multiple Myeloma Status after Stem Cell Transplantation
Zeldenrust, Steven R., Murray, David , Katzmann, Jerry A., Donato, Leslie J.

Mayo Clinic

Clinical Chemistry | November 28, 2011 | Volume: 57 | Issue: 12 | Pages: 1645-1648

10.1373/clinchem.2011.163766 | PMID 22125317 Get It

Transfusion-related acute lung injury: incidence and risk factors
Toy, Pearl, Bacchetti, Peter , Looney, Mark R. , Gropper, Michael A. , Hubmayr, Rolf D., Lowell, Clifford A. , Norris, Philip J. , Murphy, Edward L. , Weiskopf, Richard B. , Wilson, Gregory , Koenigsberg, Monique, Lee, Deanna, Schuller, Randy M. , Wu, Ping , Grimes, Barbara , Winters, Jeffrey L. , Mair, David , Hirschler, Nora V., Rosen, Rosa Sanchez, Matthay, Michael A. , Group, for the TRALI Study, Gajic, Ognjen , Gandhi, Manish J. , Group, for the TRALI Study, Winters, Jeffrey L

Mayo Clinic

Blood | November 24, 2011 | Volume: 119 | Issue: 7 | Pages: 1757-1767

10.1182/blood-2011-08-370932 | PMID 22117051 Get It

AbstractTransfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality. To determine TRALI incidence by prospective, active surveillance and to identify risk factors by a case-control study, 2 academic medical centers enrolled 89 cases and 164 transfused controls. Recipient risk factors identified by multivariate analysis were higher IL-8 levels, liver surgery, chronic alcohol abuse, shock, higher peak airway pressure while being mechanically ventilated, current smoking, and positive fluid balance. Transfusion risk factors were receipt of plasma or whole blood from female donors (odds ratio = 4.5, 95% confidence interval [CI], 1.85-11.2, P = .001), volume of HLA class II antibody with normalized background ratio more than 27.5 (OR = 1.92/100 mL, 95% CI, 1.08-3.4, P = .03), and volume of anti–human neutrophil antigen positive by granulocyte immunofluoresence test (OR = 1.71/100 mL, 95% CI, 1.18-2.5, P = .004). Little or no risk was associated with older red blood cell units, noncognate or weak cognate class II antibody, or class I antibody. Reduced transfusion of plasma from female donors was concurrent with reduced TRALI incidence: 2.57 (95% CI, 1.72-3.86) in 2006 versus 0.81 (95% CI, 0.44-1.49) in 2009 per 10 000 transfused units (P = .002). The identified risk factors provide potential targets for reducing residual TRALI.
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
Patnaik, Mrinal M. , Hodnefield, Janice M., Knudson, Ryan A., Ketterling, Rhett P. , Garcia‐Manero, Guillermo , Steensma, David P. , Pardanani, Animesh , Hanson, Curtis A. , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P , Steensma, David P

Mayo Clinic

Blood | November 17, 2011 | Volume: 119 | Issue: 2 | Pages: 569-572

10.1182/blood-2011-09-377994 | PMID 22096241 Get It

SF3B1 mutations were recently reported in myelodysplastic syndromes (MDSs), especially in the presence of ring sideroblasts (RSs). We sought to define the interaction between SF3B1 mutations, morphology, karyotype, and prognosis in MDS with more than or equal to 15% RS (MDS-RS). We studied 107 patients with MDS-RS, including 48 with refractory anemia with RS (RARS), 43 with refractory cytopenia with multilineage dysplasia (RCMD)-RS, 11 with refractory anemia with excess blasts-1 (RAEB1)–RS, and 5 with RAEB2-RS. SF3B1 mutations were detected in 53 (∼ 50%) patients: 35 RARS (73%), 16 RCMD-RS (37%), and 2 RAEB1-RS (18%). In univariate analysis, the presence of SF3B1 mutations was associated with better overall (P < .01) and leukemia-free (P < .01) survival; however, in both instances, significance was completely accounted for by World Health Organization morphologic risk categorization. In other words, when RARS and RCMD-RS were analyzed separately, there was no additional prognostic value from the presence or absence of SF3B1 mutations.
A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32
Li, Dalin , Best, Timothy, Berg, David J. Van Den, Gourraud, Pierre‐Antoine , Cortessis, Victoria K. , Skol, Andrew D. , Mack, Thomas M. , Glaser, Sally L. , Weiss, Lawrence M. , Nathwani, Bharat N., Schumacher, Fredrick R. , Edlund, Christopher K., Hwang, Amie E. , Fredericksen, Zachary S., Strong, Louise C. , Link, Brian K. , Cerhan, James R. , Conti, David V. , Onel, Kenan , Cozen, Wendy , Bhatia, Ravi , Slager, Susan L. , Habermann, Thomas M. , Robison, Leslie L. , Cerhan, James R , Link, Brian K , Conti, David V

Mayo Clinic

Blood | November 16, 2011 | Volume: 119 | Issue: 2 | Pages: 469-475

10.1182/blood-2011-03-343921 | PMID 22086417 Get It

Nodular sclerosing Hodgkin lymphoma (NSHL) is a distinct, highly heritable Hodgkin lymphoma subtype. We undertook a genome-wide meta-analysis of 393 European-origin adolescent/young adult NSHL patients and 3315 controls using the Illumina Human610-Quad Beadchip and Affymetrix Genome-Wide Human SNP Array 6.0. We identified 3 single nucleotide polymorphisms (SNPs) on chromosome 6p21.32 that were significantly associated with NSHL risk: rs9268542 (P = 5.35 × 10−10), rs204999 (P = 1.44 × 10−9), and rs2858870 (P = 1.69 × 10−8). We also confirmed a previously reported association in the same region, rs6903608 (P = 3.52 × 10−10). rs204999 and rs2858870 were weakly correlated (r2 = 0.257), and the remaining pairs of SNPs were not correlated (r2 < 0.1). In an independent set of 113 NSHL cases and 214 controls, 2 SNPs were significantly associated with NSHL and a third showed a comparable odds ratio (OR). These SNPs are found on 2 haplotypes associated with NSHL risk (rs204999-rs9268528-rs9268542-rs6903608-rs2858870; AGGCT, OR = 1.7, P = 1.71 × 10−6; GAATC, OR = 0.4, P = 1.16 × 10−4). All individuals with the GAATC haplotype also carried the HLA class II DRB1*0701 allele. In a separate analysis, the DRB1*0701 allele was associated with a decreased risk of NSHL (OR = 0.5, 95% confidence interval = 0.4, 0.7). These data support the importance of the HLA class II region in NSHL etiology.
Quality of Care in Non–Small-Cell Lung Cancer: Findings From 11 Oncology Practices in Florida
Corman, M., Lee, Ji‐Hyun , Fulp, William J. , Schreiber, Fred, Brown, R. H. , Levine, Richard M., Cartwright, Thomas H. , Abesada‐Terk, Guillermo, Kim, George P., Alemany, Carlos, Faig, Douglas, Sharp, Philip, Markham, Merry Jennifer , Bepler, Gerold , Siegel, Erin M. , Shibata, David , Malafa, Mokenge P. , Jacobsen, Paul B. , Tanvetyanon, Tawee , Markham, Merry J

Mayo Clinic

Journal of Oncology Practice | November 16, 2011 | Volume: 7 | Issue: 6 | Pages: e25-e31

10.1200/jop.2011.000228 | PMID 22379428 Get It

On the basis of this data set of participating institutions in Florida, several areas in the care of patients with non–small-cell lung cancer were identified as targets for future quality improvement efforts.